Superb overview/comparisons from Germany, published October 4, 2019.
"Chemoimmunotherapy has been standard of care in patients with chronic lymphocytic leukemia for a long time. Over the last years, novel agents have produced unprecedented outcomes in treatment-naive and relapsed/refractory chronic lymphocytic leukemia. With the advent of these targeted agents, treatment options have extensively diversified and new questions emerge. It is still unclear whether these novel agents should be used as sequential monotherapies until disease progression or if they should preferably be combined in time-limited treatment regimens aiming at deep and durable remissions. While both approaches yield high response rates and long progression-free and overall survival, it remains challenging to identify patients individually for the optimal concept. This review provides guidance in this decision process by presenting evidence on sequencing and combining novel agents and further elaborating on the advantages and drawbacks of these two concepts."